Identifying areas where drug costs are rising, and the unique challenges posed by GLP-1 drugs
Health Canada approves TRIKAFTA for additional CF mutations, increasing treatment options for patients
Pfizer plans clinical trials for a once-a-day weight-loss pill after discontinuing the twice-daily version
SVP of Benefit Services at NFP explains the areas where costs are rising and the options plan sponsors now have to deal with these increases
AI's potential to boost Canada's GDP is significant, but adoption rates and trust issues pose hurdles
FDA approves Kisunla, the second drug to slow Alzheimer's, offering a new option for early-stage patients
